Market Cap 2.62B
Revenue (ttm) 528.30M
Net Income (ttm) -56.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 310.91
Profit Margin -10.62%
Debt to Equity Ratio 1.92
Volume 2,997,300
Avg Vol 4,718,734
Day's Range N/A - N/A
Shares Out 308.24M
Stochastic %K 92%
Beta 0.56
Analysts Strong Sell
Price Target $15.36

Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 662 2000
Fax: 609 662 2001
Address:
47 Hulfish Street, Princeton, United States
JFais
JFais Oct. 25 at 2:02 AM
For this Weekend's Recap post- will be replacing $NUVB and $FOLD in "Companies I would Start With" section As both have run up significantly since entry with full size positions
0 · Reply
RGeno
RGeno Oct. 23 at 3:09 PM
$FOLD down on tiny tiny volume. I think ready to BO.🤞
0 · Reply
Hognose
Hognose Oct. 23 at 1:46 PM
0 · Reply
Hognose
Hognose Oct. 23 at 9:48 AM
$BYND $GME Want a real stock that is undervalued? Consider $FOLD fold is one of my bigger holdings.
0 · Reply
TeeMan123
TeeMan123 Oct. 22 at 7:02 PM
$FOLD green in a sea of red.. curious.. i like it!
0 · Reply
Hognose
Hognose Oct. 22 at 5:41 PM
$FOLD This right here. ✅️
0 · Reply
Hognose
Hognose Oct. 22 at 5:40 PM
$FOLD buy and hold. Great value here.
0 · Reply
Hognose
Hognose Oct. 22 at 5:27 PM
$FOLD resilience and nice chart with under valued pipeline. Buy now.
0 · Reply
Hognose
Hognose Oct. 22 at 5:26 PM
$BYND want a real good investment / trade. Go with $FOLD
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 7:40 PM
$FOLD continues to trade at lower multiples of projected sales versus 3 peers with like dollar forecasts & gross margin profiles. FOLD is currently defending its patent rights against a generic pharma hoping to sell a biosimilar. We suspect this could be the reason why FOLD does not trade at like multiples versus its peers $MIRM $TARS $KNSA Again by peers we mean those commercial-stage bios with similar revenue projections & patent lives. This is not investment advice. $IBB
2 · Reply
Latest News on FOLD
3 Of My Favorite Biotech Stocks Under $10

Sep 29, 2025, 1:15 PM EDT - 25 days ago

3 Of My Favorite Biotech Stocks Under $10

DVAX MRNA NUVB PFE


Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Jun 12, 2025, 10:14 AM EDT - 4 months ago

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma


3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 10 months ago

3 Oversold Biotech Names

AVDL JAZZ VKTX XBI


Amicus Therapeutics: Cheap Heading Into 2025

Dec 27, 2024, 1:33 PM EST - 10 months ago

Amicus Therapeutics: Cheap Heading Into 2025


JFais
JFais Oct. 25 at 2:02 AM
For this Weekend's Recap post- will be replacing $NUVB and $FOLD in "Companies I would Start With" section As both have run up significantly since entry with full size positions
0 · Reply
RGeno
RGeno Oct. 23 at 3:09 PM
$FOLD down on tiny tiny volume. I think ready to BO.🤞
0 · Reply
Hognose
Hognose Oct. 23 at 1:46 PM
0 · Reply
Hognose
Hognose Oct. 23 at 9:48 AM
$BYND $GME Want a real stock that is undervalued? Consider $FOLD fold is one of my bigger holdings.
0 · Reply
TeeMan123
TeeMan123 Oct. 22 at 7:02 PM
$FOLD green in a sea of red.. curious.. i like it!
0 · Reply
Hognose
Hognose Oct. 22 at 5:41 PM
$FOLD This right here. ✅️
0 · Reply
Hognose
Hognose Oct. 22 at 5:40 PM
$FOLD buy and hold. Great value here.
0 · Reply
Hognose
Hognose Oct. 22 at 5:27 PM
$FOLD resilience and nice chart with under valued pipeline. Buy now.
0 · Reply
Hognose
Hognose Oct. 22 at 5:26 PM
$BYND want a real good investment / trade. Go with $FOLD
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 7:40 PM
$FOLD continues to trade at lower multiples of projected sales versus 3 peers with like dollar forecasts & gross margin profiles. FOLD is currently defending its patent rights against a generic pharma hoping to sell a biosimilar. We suspect this could be the reason why FOLD does not trade at like multiples versus its peers $MIRM $TARS $KNSA Again by peers we mean those commercial-stage bios with similar revenue projections & patent lives. This is not investment advice. $IBB
2 · Reply
CaptainAmrica
CaptainAmrica Oct. 20 at 5:42 PM
$FOLD... Speculative Bio but extremely Long....See you at $15...
0 · Reply
r3y
r3y Oct. 16 at 11:28 PM
$FOLD bought here following the big boys...someone knows...
2 · Reply
Hognose
Hognose Oct. 15 at 6:14 PM
$RXRX $FOLD ready
0 · Reply
Hognose
Hognose Oct. 15 at 4:40 PM
$FOLD under the radar and ready.
0 · Reply
Hognose
Hognose Oct. 15 at 3:51 PM
$FOLD setup is here. Long and waiting for that big leg up.
0 · Reply
Estimize
Estimize Oct. 15 at 1:00 PM
Wall St is expecting 0.03 EPS for $FOLD Q3 [Reporting 11/05 BMO] http://www.estimize.com/intro/fold?chart=historical&metric_name=eps&utm_co
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 14 at 1:33 AM
The attachment compares $SNDX market cap as a multiple of FY2028 analyst consensus & cumulative 5-year analyst estimates to peer comm'l-stage non-oncology focused bios. Note analysts forecast SNDX to generate more revenues than most of these non-oncology focused peers with much higher valuations. Is SNDX's valuation being held back by a 10/25/25 PDUFA? The original intent of this post was to focus on the SNDX valuation disconnect with its non-oncology peers but we also follow $FOLD because FOLD trades at a very low multiple of projected revenues. In FOLD's case, we believe the disconnect is due to a private pharma's threat to produce a generic Galafold. Galafold is supposedly patented thru FY38. Its patents have been challenged before by TEVA to no avail. The FOLD case went to court very recently. Should FOLD prevail perhaps its valuation will catch up with its peers? $HROW $BCRX ? We did exclude some SNDX non-oncology peers like SRPT HRMY & $XERS for various reasons
1 · Reply
Doozio
Doozio Oct. 11 at 6:26 PM
$XBI don’t $FOLD unless yo gotta $AXSM body! If so? $FBRX about it . 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Oct. 11 at 2:43 PM
Chop chop don’t $FOLD the tightness wen papa huckleberry is coming it’s still 🐒🍌🧠⏰♾️ $MAMA said.
0 · Reply
Doozio
Doozio Oct. 8 at 7:28 PM
Thru ⏰ not price. Who is gonna $FOLD da $NUTX wen da huckleberries are coming during 🐒🍌🧠⏰♾️
1 · Reply
HateTradingStocks
HateTradingStocks Oct. 4 at 10:58 PM
$FOLD I hate babies. I hate the way they smile and giggle. My ex-girlfriend used to smile and giggle like that. Someone ran her over in a terrible car accident. I feel bad for her now. She can’t walk and doesn’t smile or giggle anymore. Sometimes she poops herself. I broke up with her once that happened.
0 · Reply
Doozio
Doozio Oct. 4 at 10:27 PM
Go ahead 🐑. They told yo to $FOLD in 2021 n FBRXetabout. All da 🐑 been SPOT and yo estimate it’s 🐒🍌🧠⏰♾️
0 · Reply